ArticleNeurology and therapy2026
Patient- and Caregiver-Reported Burden and Quality of Life in Generalised Myasthenia Gravis: A Multinational Real-World Survey in the Asia-Pacific Region.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUnderstanding patient- and caregiver-reported burden of generalised myasthenia gravis (gMG) is essential to inform region-specific management and policy decisions. However, real-world data from the Asia-Pacific region remain limited.
methodsData were drawn from the Adelphi Real World gMG Disease Specific Programme™, a cross-sectional survey of neurologists and their patients with gMG conducted in Australia, China, Japan, Malaysia, South Korea, and Taiwan between July 2023 and January 2024. Neurologists reported patient demographics, clinical characteristics, and perceived patient quality of life (QoL). Patients, and patients' caregivers provided answers to self-reported outcome measures, including the EQ-5D-5L, corresponding to status at the time of survey. Analyses were descriptive other than weighted kappa analyses used to measure neurologist-patient agreement on subjective patient QoL at the time of survey.
resultsOverall, 163 neurologists reported data for 434 patients, of whom 205 self-reported data alongside 151 caregivers. Most patients were female (58.5%), with a mean (SD) age of 51.4 (15.2) years, and received caregiver support (71.4%). Patients reported deficits across all EQ-5D-5L domains, including usual activities (79.4%), and moderate to extreme anxiety/depression (29.4%), with a mean (SD) index score of 0.72 (0.23). Most patients (54.6%) had a FACIT-Fatigue score < 30, indicating severe fatigue, and 45.0% of patients had reduced employment due to gMG. A kappa value of 0.2692 indicated a fair agreement between neurologist and patient perceived patient QoL. Mean (SD) patient absenteeism was 11.8% (20.8%), presenteeism 39.2% (22.5%), overall work productivity loss of 42.9% (23.9%), and activity impairment of 51.3% (23.9%). Caregivers reported a mean (SD) 27.6% (19.6%) overall work productivity loss and 47.0% (24.1%) activity impairment.
conclusionPatients and their caregivers reported substantial burden to QoL, including impaired work productivity, limitations in activities of daily living, fatigue, and anxiety/depression. Further research into health-policy initiatives is warranted to more effectively address these unmet needs in the Asia-Pacific.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.